Olaparib in ovarian cancer with BRCA mutation

被引：5

作者：

Pujade-Lauraine, Eric ^{[1
]}

Combe, Pierre ^{[2
]}

机构：

[1] GH Paris Ctr, Ctr Canc Femme & Rech Clin, F-75181 Paris 04, France

[2] Hop Europeen Georges Pompidou, Serv Oncol Med, F-75015 Paris, France

来源：

BULLETIN DU CANCER | 2015年 / 102卷 / 06期

关键词：

BRCA; Ovarian cancer; Olaparib; PARP;

D O I：

10.1016/S0007-4551(15)31221-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.

引用

页码：S82 / S84

页数：3

共 50 条

[21] Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
Chee Khoon Lee
Clare Scott
Geoffrey J. Lindeman
Anne Hamilton
Elizabeth Lieschke
Emma Gibbs
Rebecca Asher
Heath Badger
Robin Paterson
Lauren Macnab
Edmond Michael Kwan
Prudence A. Francis
Frances Boyle
Michael Friedlander
British Journal of Cancer, 2019, 120 : 279 - 285
[22] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
Tucker, Helen
Charles, Zoe
Robertson, Janet
Adam, Jane
LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
[23] UK BRCA mutation testing in patients with ovarian cancer
George, Angela
BRITISH JOURNAL OF CANCER, 2015, 113 : S17 - S21
[24] PROGNOSTIC FACTORS FOR BRCA MUTATION IN OVARIAN CANCER PATIENTS
Lee, N.
No, J. H.
Kim, Y. B.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A486 - A487
[25] UK BRCA mutation testing in patients with ovarian cancer
Angela George
British Journal of Cancer, 2015, 113 : S17 - S21
[26] Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Lee, Jung-Min
Hays, John L.
Annunziata, Christina M.
Noonan, Anne M.
Minasian, Lori
Zujewski, Jo Anne
Yu, Minshu
Gordon, Nicolas
Ji, Jiuping
Sissung, Tristan M.
Figg, William D.
Azad, Nilofer
Wood, Bradford J.
Doroshow, James
Kohn, Elise C.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (06):
[27] Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study
Sehouli, J.
Hilpert, F.
Welslau, M. K.
Grabowski, J. P.
Schneeweiss, A.
Hartkopf, A. D.
Becker, S.
Bauerschlag, D.
Fasching, P. A.
Brandi, C.
Rehbein, J-K.
Glowik, R. M.
Marme, F.
ANNALS OF ONCOLOGY, 2024, 35 : S582 - S582
[28] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, Bella
Shapira-Frommer, Ronnie
Schmutzler, Rita K.
Audeh, M. William
Friedlander, Michael
Balmana, Judith
Mitchell, Gillian
Fried, Georgeta
Stemmer, Salomon M.
Hubert, Ayala
Rosengarten, Ora
Steiner, Mariana
Loman, Niklas
Bowen, Karin
Fielding, Anitra
Domchek, Susan M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) : 244 - 250
[29] Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation
Saillant, Arnaud
Flippot, Ronan
BULLETIN DU CANCER, 2021, 108 (02) : 140 - 142
[30] Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
Gallardo-Rincon, Dolores
Montes-Servin, Edgar
Alamilla-Garcia, Gabriela
Montes-Servin, Elizabeth
Bahena-Gonzalez, Antonio
Cetina-Perez, Lucely
Vasquez, Flavia Morales
Cano-Blanco, Claudia
Coronel-Martinez, Jaime
Gonzalez-Ibarra, Ernesto
Espinosa-Romero, Raquel
Alvarez-Gomez, Rosa Maria
Pedroza-Torres, Abraham
Castro-Eguiluz, Denisse
FRONTIERS IN GENETICS, 2022, 13

← 1 2 3 4 5 →